ENDRA Life Sciences
NDRA
8 hedge funds and large institutions have $417K invested in ENDRA Life Sciences in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
28% more capital invested
Capital invested by funds: $325K → $417K (+$91.4K)
14% more funds holding
Funds holding: 7 → 8 (+1)
1.53% more ownership
Funds ownership: 6.16% → 7.68% (+1.5%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$83.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$555 |
| 3 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$13.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$45 |
| 3 |
Citigroup
New York
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
Altium Capital Management
New York
| $241K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $98K | +$83.5K | +21,078 | New |
|
|
VFT
3
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $47.1K | +$40.1K | +10,121 | New |
|
|
4
Morgan Stanley
New York
| $16.5K | -$13.5K | -3,400 | -49% |
|
|
VCM
5
Vanguard Capital Management
Malvern,
Pennsylvania
| $13.1K | +$11.2K | +2,816 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $707 | +$555 | +140 | +1,167% |
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $88 | – | – | – |
|
|
CIAM
8
Caitong International Asset Management
Hong Kong
| $19 | +$16 | +4 | New |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$45 | -10 | Closed |
|
|
10
Citigroup
New York
| – | -$5 | -1 | Closed |
|
NDRA Hedge Fund Activity: Q1 2026 in Review
8 of the 8,139 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q1 2026, worth a combined $417K — up 28% from $325K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NDRA positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $83.5K. The largest seller was Morgan Stanley, cutting an estimated $13.5K.
- 8 institutional investors held ENDRA Life Sciences (NDRA) as of Q1 2026, up from 7 in Q4 2025.
- Funds reported $417K of ENDRA Life Sciences stock for Q1 2026, up 28% quarter-over-quarter.
- 4 funds opened new ENDRA Life Sciences positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest ENDRA Life Sciences buyer in Q1 2026 was Geode Capital Management, an estimated $83.5K added.
- The largest ENDRA Life Sciences seller in Q1 2026 was Morgan Stanley, an estimated $13.5K sold.
Based on aggregated 13F filings for Q1 2026.